Evidence map›Paper›PMID 33731798›Full record

ArticleScientific reports2021

Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis.

Philip A Waghorn, Diego S Ferreira, Derek J Erstad, Nicholas J Rotile, Ricard Masia, Chloe M Jones, Chuantao Tu, Mozhdeh Sojoodi, Yin-Ching I Chen, Franklin Schlerman and 5 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Lysyl oxidase regulation and protein aldehydes in the injured newborn lung.American journal of physiology. Lung cellular and molecular physiology · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Philip A WaghornDepartment of Radiology, Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Institute for Innovation in Imaging, Harvard Medical School, 149 13th St., Boston, MA, 02129, USA.
Diego S FerreiraDepartment of Radiology, Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Institute for Innovation in Imaging, Harvard Medical School, 149 13th St., Boston, MA, 02129, USA.
Derek J ErstadDivision of Surgical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, 02114, USA.
Nicholas J RotileDepartment of Radiology, Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Institute for Innovation in Imaging, Harvard Medical School, 149 13th St., Boston, MA, 02129, USA.
Ricard MasiaDivision of Surgical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, 02114, USA.
Chloe M JonesDepartment of Radiology, Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Institute for Innovation in Imaging, Harvard Medical School, 149 13th St., Boston, MA, 02129, USA.
Chuantao TuDepartment of Radiology, Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Institute for Innovation in Imaging, Harvard Medical School, 149 13th St., Boston, MA, 02129, USA.
Mozhdeh SojoodiDivision of Surgical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, 02114, USA.
Yin-Ching I ChenDepartment of Radiology, Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Institute for Innovation in Imaging, Harvard Medical School, 149 13th St., Boston, MA, 02129, USA.
Franklin SchlermanPfizer, Cambridge, MA, 02139, USA.
Jeremy WellenPfizer, Cambridge, MA, 02139, USA.
Robert V P MartinezPfizer, Cambridge, MA, 02139, USA.
Kenneth K TanabeDivision of Surgical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, 02114, USA.
Bryan C FuchsDivision of Surgical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, 02114, USA.
Peter CaravanDepartment of Radiology, Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Institute for Innovation in Imaging, Harvard Medical School, 149 13th St., Boston, MA, 02129, USA. pcaravan@mgh.harvard.edu.
Massachusetts General Hospital · USAthinoula A. Martinos Center for Biomedical Imaging · USPfizer (United States) · US

Funding

Molecular MR Imaging of Hepatic FibrogenesisR01DK121789 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Peter D Caravan · 2019 to 2026
$5.0M
Stable, High Relaxivity MRI Contrast AgentsR01EB009062 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D · 2009 to 2017
$4.9M
Molecular Imaging of Liver FibrosisR01DK104956 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI TANABE, KENNETH K · 2015 to 2019
$2.7M
Molecular Imaging of Renal FibrogenesisU01DK104302 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D · 2014 to 2019
$2.1M
Electronics Upgrade for 11.7 TS10OD025234 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D · 2018 to 2018
$595k
HPLC-ICP-MS SystemS10OD010650 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D · 2013 to 2013
$371k
NIBIB NIH HHS R01 EB009062NIDDK NIH HHS R01 DK104956NIDDK NIH HHS R01 DK121789NIDDK NIH HHS U01 DK104302NIH HHS S10 OD010650NIH HHS S10 OD025234
6 · The paper itself

Abstract

Non-alcoholic steatohepatitis (NASH) is an increasing cause of chronic liver disease characterized by steatosis, inflammation, and fibrosis which can lead to cirrhosis, hepatocellular carcinoma, and mortality. Quantitative, noninvasive methods for characterizing the pathophysiology of NASH at both the preclinical and clinical level are sorely needed. We report here a multiparametric magnetic resonance imaging (MRI) protocol with the fibrogenesis probe Gd-Hyd to characterize fibrotic disease activity and steatosis in a common mouse model of NASH. Mice were fed a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) to induce NASH with advanced fibrosis. Mice fed normal chow and CDAHFD underwent MRI after 2, 6, 10 and 14 weeks to measure liver T1, T2*, fat fraction, and dynamic T1-weighted Gd-Hyd enhanced imaging of the liver. Steatosis, inflammation, and fibrosis were then quantified by histology. NASH and fibrosis developed quickly in CDAHFD fed mice with strong correlation between morphometric steatosis quantification and liver fat estimated by MRI (r = 0.90). Sirius red histology and collagen quantification confirmed increasing fibrosis over time (r = 0.82). Though baseline T1 and T2* measurements did not correlate with fibrosis, Gd-Hyd signal enhancement provided a measure of the extent of active fibrotic disease progression and correlated strongly with lysyl oxidase expression. Gd-Hyd MRI accurately detects fibrogenesis in a mouse model of NASH with advanced fibrosis and can be combined with other MR measures, like fat imaging, to more accurately assess disease burden.

Indexed as

Magnetic Resonance ImagingAnimalsContrast MediaCoordination ComplexesDiet, High-FatDisease Models, AnimalGadoliniumLiverMaleMiceNon-alcoholic Fatty Liver DiseaseContrast MediaCoordination ComplexesGadolinium

Identifiers

PMID33731798
PMCPMC7971064
OpenAlexW3137410981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.